<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69831">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02196701</url>
  </required_header>
  <id_info>
    <org_study_id>W14-406</org_study_id>
    <nct_id>NCT02196701</nct_id>
  </id_info>
  <brief_title>Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of the use of the
      combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in
      suboptimal responders to ADA monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving a satisfactory response based on investigator assessment</measure>
    <time_frame>From Week 16 to Week 24</time_frame>
    <description>Evaluated via the Investigator Satisfaction Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving a satisfactory response based on subject self-assessment</measure>
    <time_frame>From Week 16 to Week 24</time_frame>
    <description>Evaluated via the Subject Satisfaction Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects (primary and secondary sub-optimal responders) achieving reduction in PASI</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>PASI score is monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of primary and secondary sub-optimal responders achieving a clinical response</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Clinical response defined as a PGA of &quot;Clear&quot; or &quot;Minimal&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI) scores</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>DLQI questionnaire will be completed by all subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of primary sub-optimal responders achieving reduction in PASI</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>PASI score is monitored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of secondary sub-optimal responders achieving reduction in PASI</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>PASI score is monitored</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>adalimumab and methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm- all patients will receive adalimumab and methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>adalimumab and methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>adalimumab and methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who have been on ADA monotherapy (40 mg eow or greater) for at least 16
             weeks but who in the opinion of the Investigator have shown a sub-optimal response to
             treatment and have a PGA of &gt; 3 and a PASI of &gt; 5; or Subjects who after an initial
             positive response to ADA monotherapy (40 mg eow or greater) have failed to maintain
             an optimal level of response, based on the opinion of the Investigator, and have a
             PGA of &gt; 3 and a PASI of &gt; 5;

          2. Subjects who are receiving 40 mg ADA once weekly must be on ADA 40 mg eow for 8 weeks
             prior to screening;

          3. Subjects with at least a 6 month history of chronic plaque Ps;

          4. Subjects greater than or equal to 18 years of age;

          5. If female, subject is either not of childbearing potential, defined as postmenopausal
             for at least 1 year or surgically sterile or is of childbearing potential and is
             practicing birth control;

          6. The results of the serum pregnancy test performed during the Screening Period and
             urine pregnancy test performed at the Baseline Visit must be negative;

          7. Subject is judged to be in good general health as determined by the Principal
             Investigator;

          8. Subjects must be evaluated for latent TB infection;

          9. Subjects must be able and willing to provide written informed consent and comply with
             the requirements of the study protocol;

         10. Subjects must be willing and able to self-administer subcutaneous (SC) injections or
             have a qualified person available to administer SC injections.

        Exclusion Criteria:

          1. Subject has any contraindications to MTX or ADA;

          2. Subject has a previous failed response or poor tolerance to ADA;

          3. Subject has a poorly controlled medical condition which, in the opinion of the
             Investigator, would put the subject at risk by participation in the study;

          4. Subject has a history of clinically significant hematologic, renal or liver disease;

          5. Subject has a history of neurologic symptoms suggestive of central nervous system
             (CNS) demyelinating disease and/or diagnosis of central demyelinating disease;

          6. Subject has evidence of dysplasia or history of malignancy (including lymphoma and
             leukemia) other than a successfully treated non-metastatic cutaneous squamous cell or
             basal cell carcinoma or localized carcinoma in situ of the cervix;

          7. Subject has a history of listeriosis, histoplasmosis, untreated TB, persistent
             chronic infections, or recent active infections requiring hospitalization or
             treatment with intravenous (iv) anti-infectives within 30 days or oral
             anti-infectives within 14 days prior to the Baseline visit;

          8. Subject is known to have immune deficiency, history of HIV or is immunocompromised;

          9. Subject currently uses or plans to use anti-retroviral therapy at any time during the
             study;

         10. Female subject who is pregnant or breast-feeding or considering becoming pregnant
             during the study or for 150 days after the last dose of study medication;

         11. Subject has a history of clinically significant drug or alcohol usage in the last
             year or cannot maintain an alcohol intake of 30 g a day or less throughout the study
             (one standard drink is defined as 180 mL/6 oz (approx. 10 g) of wine, 360 mL/12 oz
             (approx. 15 g) of regular beer, or 45 mL/1.5 oz (approx. 10 g) of spirits;

         12. Screening clinical laboratory analyses show any of the following abnormal laboratory
             results:

               -  Aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 2x the upper limit
                  of normal (ULN);

               -  Serum total bilirubin &gt; 1.5 mg/dL (&gt; 26 micromol/L), except for subjects with
                  Gilbert's Syndrome;

               -  Creatinine &gt; 1.5 mg/dL (133 micromol/L) in subjects ≤ 65 years old and &gt; upper
                  limit of normal range in subjects &gt; 65;

               -  Positive Hepatitis B or C serology indicative of previous or current infection.

         13. Subject is considered by the Investigator, for any reason, to be an unsuitable
             candidate for the study;

         14. The following treatments are prohibited for all subjects during the study:

        1. Phototherapy (PUVA (within 4 weeks of the Baseline Visit) and/or UVB (within 2 weeks of
        the Baseline Visit); 2. Other biologic therapies (including any other anti-TNF) within 4
        weeks of the Baseline Visit; 3. Any investigational agents of chemical or biologic nature
        within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to the
        Baseline visit ; 4. Any other systemic drug therapies for Ps within 4 weeks of the
        Baseline Visit; 5. Oral or injectable corticosteroids, new prescription topical therapies,
        or changes in the concentration of current prescription topical therapies (including
        corticosteroids) that are being used, within 2 weeks of the Baseline Visit. Subjects may
        continue using previously prescribed topical therapies (including corticosteroids) during
        the study. 15. Prior exposure to biologics that have a potential or known association with
        Progressive multifocal leukoencephalopathy PML (i.e., natalizumab (Tysabri®) or rituximab
        (Rituxan®)); 16. Subjects with any active viral infection that based on the investigator's
        clinical assessment makes the subject an unsuitable candidate for the study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc-André Raymond, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maritime Medical Reseach Center /ID# 128352</name>
      <address>
        <city>Bathurst</city>
        <zip>E2A 4Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirk Barber Research, Calgary, Alberta, Canada /ID# 126518</name>
      <address>
        <city>Calgary</city>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratica Medical /ID# 126317</name>
      <address>
        <city>Edmonton</city>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research Inc. /ID# 126352</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc. /ID# 126318</name>
      <address>
        <city>Markham</city>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinic of Dr. Robern /ID# 126595</name>
      <address>
        <city>Ottawa</city>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Melinda Gooderham Medicine Professionnale Corporation /ID# 126773</name>
      <address>
        <city>Peterborough</city>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Afsaneh Alavi Corporation /ID# 127634</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dre. Angelique Gagne-Henley M.D. Inc. /ID# 133833</name>
      <address>
        <city>Saint-Jerome</city>
        <zip>J7Z 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc. /ID# 126520</name>
      <address>
        <city>Surrey</city>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research /ID# 127803</name>
      <address>
        <city>Surrey</city>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Toronto /ID# 126519</name>
      <address>
        <city>Toronto</city>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research /ID# 126351</name>
      <address>
        <city>Waterloo</city>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Clinic, Manitoba, Canada /ID# 126320</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>July 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methotrexate</keyword>
  <keyword>adalimumab</keyword>
  <keyword>biologic</keyword>
  <keyword>psoriasis</keyword>
  <keyword>Tumor necrosis factor (TNF)-α inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
